Last reviewed · How we verify
SUVN-911
At a glance
| Generic name | SUVN-911 |
|---|---|
| Sponsor | Suven Life Sciences Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients (PHASE2)
- Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients (PHASE2)
- Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects (PHASE1)
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |